A selected region of a digitized H&E-stained slide [Image courtesy of PathAI]
In a recent conversation with Dr. Andy Beck, co-founder and CEO of PathAI, we had the opportunity to discuss PathExplore, an AI-driven platform that aims to transform the way tumor microenvironment (TME) analysis is conducted. Traditional methods such as manual pathology, multiplex immunofluorescence and single-cell omics often face limitations, including high costs or tissue consumption. PathExplore addresses these challenges by using AI to analyze digitized H&E slides, which are widely available and don’t necessitate advanced assays or equipment.In the following interview, Dr. Beck highlights the advantages of PathExplore, such as its ability to bridge the gap between H&E and high-resolution modalities such as multiplex and single-cell RNA sequencing and its potential for rapidly scaling biomarkers. Additionally, t…